Abstract:Background Existing studies of PLK1 in cervical cancer had several flaws. The methods adopted by those studies of detecting PLK1 expression in cervical cancer were single and there lacks comprehensive evaluation of the clinico-pathological significance of PLK1 in cervical cancer. Methods A total of 303 cervical tissue samples were collected for in-house tissue microarrays. Immunohistochemistry was performed for evaluating PLK1 expression between cervical cancer (including cervical squamous cell carcinoma (CESC) and cervical adenocarcinoma) and non-cancer samples. The Expression Atlas database was searched for querying PLK1 expression in different cervical cancer cell lines and different tissues in the context of pan-cancer. Standard mean difference (SMD) was calculated and the summarized receiver’s operating characteristics (SROC) curves were plotted for integrated tissue microarrays, exterior high-throughput microarrays and RNA sequencing data as further verification. The effect of PLK1 expression on the overall survival, disease-free survival and event-free survival of cervical cancer patients was analyzed through Kaplan Meier survival curves for cervical cancer patients from RNA-seq and GSE44001 datasets. The gene mutation and alteration status of PLK1 in cervical cancer was inspected in COSMIC and cBioPortal databases. Functional enrichment analysis was performed for genes correlated with PLK1 from aggregated RNA-seq and microarrays. Results A total of 963 cervical cancer samples and 178 non-cancer samples were collected from in-house tissue microarrays and exterior microarrays and RNA-seq datasets. The combined expression analysis supported overexpression of PLK1 in CESC, cervical adenocarcinoma and all types of cervical cancer (SMD = 1.59, 95%CI [0.56–2.63]; SMD = 2.99, 95%CI [0.75–5.24]; SMD = 1.57, 95% CI [0.85–2.29]) and the significant power of PLK1 expression in distinguishing CESC or all types of cervical cancer samples from non-cancer samples (AUC = 0.94, AUC = 0.92). Kaplan-Meier survival curves showed that the event-free survival rate of cervical cancer patients with higher expression of PLK1 was shorter than that of patients with lower PLK1 (HR = 2.020, P = 0.0197). Genetic alteration of PLK1 including missense mutation and mRNA low occurred in 6% of cervical cancer samples profiled in mRNA expression. Genes positively or negatively correlated with PLK1 were mainly assembled in pathways such as DNA replication, cell cycle, mismatch repair, Ras signaling pathway, melanoma, EGFR tyrosine kinase inhibitor resistance and homologous recombination ( P < 0.05). Conclusions Here, we provided sufficient evidence of PLK1 overexpression in cervical cancer. The overexpression of PLK1 in cervical cancer and the contributory effect of it on clinical progression indicated the hopeful prospect of PLK1 as a biomarker for cervical cancer.

Mitosis Arrest Caused by Inhibition of PLK1 Expression in Gastric Cancer MKN45 Cells

Inhibitory Effect of Polo-like Kinase 1 Depletion on Mitosis and Apoptosis of Gastric Cancer Cells

Inhibition of plk1 Expression Leads to Increased CyclinB/cdc2 Complex Activity in Gastric Cancer Cells

[Study of Growth Inhibition of Gastric Cancer Cells by Srna Targeting Polo Like Kinase 1 in Vitro and Vivo].

Inhibition of Plk-1 gene expression enhences 5-Fu and CDDP induced apoptosis of gastric cancer cells

Involvement of Polo-like Kinase 1 (plk1) in Mitotic Arrest by Inhibition of Mitogen-activated Protein Kinase-Extracellular Signal-regulated Kinase-Ribosomal S6 Kinase 1

[Mitotic Arrest of Gastric Cancer Cells Induced by Silencing of STK15 Gene].

Phospholipase C Delta 1 is a Novel 3p22.3 Tumor Suppressor Involved in Cytoskeleton Organization, with Its Epigenetic Silencing Correlated with High-Stage Gastric Cancer

Involvement of Polo-like Kinase 1 (plk1) in Mitotic Arrest by Inhibition of Mitogen-activated Protein Kinase-Extracellular Signal-regulated Kinase-Ribosomal S6 Kinase 1 (MEK-ERK-RSK1) Cascade*

Significance of Polo Like Kinase1 and Protein Expression in Gastric Carcinomas

Involvement of Polo-like Kinase 1 (plk1) in Quiescence Regulation of Cancer Stem-Like Cells of the Gastric Cancer Cell Lines

Study on folate deficiency and Polo-like kinase 1 (PLK-1) siRNA in synergistically inhibiting the growtho f gsa tric carcinoma cell lines

Polo Like Kinase 1 Expression and Prognostic Value in Gastric Carcinomas

The Balance of Polo-like Kinase 1 in Tumorigenesis

Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.

POLO-LIKE KINASE1 GENE EXPRESSION AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN GASTRIC CARCINOMA

Overexpression of PlK-1 gene effects of PlK-1 gene on the chemotherapeutic sensitivity of pancreatic carcinoma cell line AsPC-1 response to gemcitabine

Silencing of polo-like kinase 2 increases cell proliferation and decreases apoptosis in SGC-7901 gastric cancer cells.

Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.

Polo like kinase 1 expression in cervical cancer tissues generated from multiple detection methods

The Expression of Plk-1 in Cervical Carcinoma: A Possible Target for Enhancing Chemosensitivity